07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

BXQ-350: Phase I started

Bexion began an open-label, U.S. Phase I trial to evaluate IV BXQ-350 in about 40 patients, including those with recurrent high-grade gliomas. A dose-escalation part will identify the dose to be used in the second...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Company News

Bexion board of directors update

Bexion Pharmaceuticals LLC , Cleveland, Ohio   Business: Cancer   Appointed: Lester Crawford, formerly FDA commissioner  ...
07:00 , Apr 28, 2008 |  BC Week In Review  |  Company News

Bexion, Molecular Targeting Technologies deal

Molecular Targeting will use Bexion's nanovesicle technology to develop cancer diagnostic imaging reagents, with an initial focus on gliomas. Molecular Targeting will have rights to resulting diagnostics. Financial terms were not disclosed. Bexion Pharmaceuticals LLC...